FDA grants 510(k) clearance for NanoString in vitro breast cancer diagnostic assay
 

NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Prosigna? Breast Cancer Prognostic Gene Signature Assay...

More...